Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-Nmda Receptor Encephalitis and Assess Markers of Disease

NCT04372615 is registered in ClinicalTrials.gov with University of Utah as lead sponsor.

NCT NCT04372615
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04372615 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-Nmda Receptor Encephalitis and Assess Markers of Disease
Lead sponsor
University of Utah
Phase
Phase 2
Overall status
Recruiting
Start date
March 30, 2022
Completion date
September 30, 2028
Enrollment
116 (estimated)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune encephalitis, encephalitis